Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab

Clinical Transplantation

Volumn 28, Issue 5, 2014, Pages 546-553

  Kahwaji, Joseph ^a   Najjar, Reiad ^a   Kancherla, Deepika ^a   Villicana, Rafael ^a   Peng, Alice ^a   Jordan, Stanley ^a   Vo, Ashley ^a   Haas, Mark ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antibodies; Desensitization; Kidney transplant; Outcomes; Pathology; Rejection

Indexed keywords

ANTIBODY; CREATININE; DONOR SPECIFIC ANTIBODY; IMMUNOGLOBULIN; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ANTIBODY MEDIATED REJECTION; ARTICLE; BIOPSY; CAPILLARITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DRUG EFFECT; GLOMERULITIS; GLOMERULOPATHY; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; OUTCOME ASSESSMENT; PERITUBULAR CAPILLARITIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TRANSPLANT GLOMERULOPATHY; TREATMENT OUTCOME; TREATMENT RESPONSE; ALLOTRANSPLANTATION; COMPLICATION; DRUG EFFECTS; FOLLOW UP; GLOMERULONEPHRITIS; GRAFT REJECTION; INFLAMMATION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; PATHOLOGY; RISK FACTOR; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFLAMMATION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84899850347     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12345     Document Type: Article

References (27)

1. Issa N, Cosio FG, Gloor JM et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008: 86: 681.
2. Sis B, Campbell PM, Mueller T et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007: 7: 1743.
3. Cosio FG, Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy. Am J Transplant 2008: 8: 492.
4. John R, Konvalinka A, Tobar A, Kim S, Reich H, Herzenberg A. Determinants of long-term graft outcome in transplant glomerulopathy. Transplantation 2010: 90: 757.
5. López Jiménez V, Fuentes L, Jiménez T et al. Transplant glomerulopathy: clinical course and factors relating to graft survival. Transplant Proc 2012: 44: 2599.
6. Hong YA, Kim HG, Choi SR et al. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection. Transplant Proc 2012: 44: 182.
7. Billing H, Rieger S, Süsal C et al. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int 2012: 25: 1165.
8. Rostaing L, Guilbeau-Frugier C, Fort M, Mekhlati L, Kamar N. Treatment of symptomatic transplant glomerulopathy with rituximab. Transpl Int 2009: 22: 906.
9. Sis B, Einecke G, Chang J et al. Cluster analysis of lesions in nonselected kidney transplant biopsies: microcirculation changes, tubulointerstitial inflammation and scarring. Am J Transplant 2010: 10: 421.
10. Sis B, Jhangri GS, Riopel J et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012: 12: 1168.
11. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008: 8: 753.
12. Solez K, Colvin RB, Racusen LC et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007: 7: 518.
13. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
14. Kieran N, Wang X, Perkins J et al. Combination of peritubular c4d and transplant glomerulopathy predicts late renal allograft failure. J Am Soc Nephrol 2009: 20: 2260.
15. Papadimitriou J, Drachenberg C, Munivenkatappa R et al. Glomerular inflammation in renal allografts biopsies after the first year: cell types and relationship with antibody-mediated rejection and graft outcome. Transplantation 2010: 90: 1478.
16. Vo A, Choi J, Kahwaji J et al. Abstract #A841 long term outcomes of highly-HLA sensitized, (PRA>80%) (HS) patients receiving desensitization with IVIG or IVIG+Rituximab: a retrospective single center analysis. Am J Transplant 2013: 13(Suppl. 5): 1.
17. Jordan SC, Pescovitz MD. Presensitization: the problem and its management. Clin J Am Soc Nephrol 2006: 1: 421.
18. Vo AA, Peng A, Toyoda M et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010: 89: 1095.
19. Takagi T, Ishida H, Shirakawa H, Shimizu T, Tanabe K. Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation 2010: 89: 1466.
20. Takagi T, Ishida H, Shirakawa H, Shimizu T, Tanabe K. Changes in anti-HLA antibody titers more than 1 year after desensitization therapy with rituximab in living-donor kidney transplantation. Transpl Immunol 2010: 23: 220.
21. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008: 359: 242.
22. Kohei N, Hirai T, Omoto K, Ishida H, Tanabe K. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant 2012: 12: 469.
23. Loupy A, Suberbielle-Boissel C, Zuber J et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010: 89: 1403.
24. Smith RN, Malik F, Goes N et al. Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transpl Immunol 2012: 27: 107.
25. Billing H, Rieger S, Ovens J et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008: 86: 1214.
26. Haas M, Mirocha J. Early ultrastructural changes in renal allografts: correlation with antibody-mediated rejection and transplant glomerulopathy. Am J Transplant 2011: 11: 2123.
27. Wavamunno MD, O'Connell PJ, Vitalone M et al. Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am J Transplant 2007: 7: 2757.